Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK11 | Q15759 | 18/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 18/20 | 0.51 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.49 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL243524 | 0.92 | MAPK14 (0.51) | MAPK11MAPK14MAPK13MAPK12 | |
| SCHEMBL243632 | 0.87 | MAPK11 (0.50) | MAPK11MAPK14MAPK13MAPK12 | |
| SCHEMBL242057 | 0.85 | HDAC1 (0.58) | MAPK11MAPK14HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL240229 | 0.85 | MAPK11 (0.48) | MAPK11MAPK14MAPK13MAPK12 | |
| SCHEMBL240698 | 0.85 | MAPK14 (0.57) | MAPK11MAPK14MAPK13MAPK12HPGD | |
| SCHEMBL240700 | 0.84 | MAPK14 (0.62) | MAPK11MAPK14 | |
| SCHEMBL243459 | 0.84 | MAPK14 (0.58) | MAPK11MAPK14MAPK13MAPK12HPGD | |
| SCHEMBL244307 | 0.84 | MAPK11 (0.55) | MAPK11MAPK14MAPK13MAPK12HPGD | |
| SCHEMBL239218 | 0.82 | MAPK14 (0.53) | MAPK11MAPK14MAPK13MAPK12HPGD | |
| SCHEMBL242798 | 0.80 | LMNA (0.72) | HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130035346-A1 | AMIDE DERIVATIVES BEARING A CYCLOPROPYLAMINOACARBONYL SUBSTITUENT USEFUL AS CYTOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2013-02-07 | — | — | US | claimed |
| US-20120004243-A1 | AMIDE DERIVATIVES BEARING A CYCLOPROPYLAMINOACARBONYL SUBSTITUENT USEFUL AS CYTOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2012-01-05 | — | — | US | claimed |
| CN-1918134-B | Amide derivatives with cyclopropylaminocarbonyl substituents as cytokine inhibitors | ASTRAZENECA AB (SE) | 2010-11-10 | — | — | CN | claimed |
| EP-1699766-B1 | AMIDE DERIVATIVES BEARING A CYCLOPROPYLAMINOACARBONYL SUBSTITUENT USEFUL AS CYTOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2010-08-11 | — | — | EP | claimed |
| US-20070135440-A1 | Amide derivatives bearing a cyclopropylaminoacarbonyl substituent useful as cytokine inhibitors | ASTRAZENECA AB (SE) | 2007-06-14 | — | — | US | claimed |
| CN-1918134-A | Amide derivatives with cyclopropylaminocarbonyl substituents as cytokine inhibitors | ASTRAZENECA AB (SE) | 2007-02-21 | — | — | CN | claimed |
| US-8742124-B2 | Amide derivatives bearing a cyclopropylaminoacarbonyl substituent useful as cytokine inhibitors | ASTRAZENECA AB (SE) | 2014-06-03 | — | — | US | disclosed |
| US-20130035346-A1 | AMIDE DERIVATIVES BEARING A CYCLOPROPYLAMINOACARBONYL SUBSTITUENT USEFUL AS CYTOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2013-02-07 | — | — | US | disclosed |
| US-20120004243-A1 | AMIDE DERIVATIVES BEARING A CYCLOPROPYLAMINOACARBONYL SUBSTITUENT USEFUL AS CYTOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2012-01-05 | — | — | US | disclosed |
| US-7943776-B2 | Amide derivatives bearing a cyclopropylaminoacarbonyl substituent useful as cytokine inhibitors | ASRAZENECA AB (SE) | 2011-05-17 | — | — | US | disclosed |
| CN-1918134-B | Amide derivatives with cyclopropylaminocarbonyl substituents as cytokine inhibitors | ASTRAZENECA AB (SE) | 2010-11-10 | — | — | CN | disclosed |
| EP-1699766-B1 | AMIDE DERIVATIVES BEARING A CYCLOPROPYLAMINOACARBONYL SUBSTITUENT USEFUL AS CYTOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2010-08-11 | — | — | EP | disclosed |
| US-20070135440-A1 | Amide derivatives bearing a cyclopropylaminoacarbonyl substituent useful as cytokine inhibitors | ASTRAZENECA AB (SE) | 2007-06-14 | — | — | US | disclosed |
| CN-1918134-A | Amide derivatives with cyclopropylaminocarbonyl substituents as cytokine inhibitors | ASTRAZENECA AB (SE) | 2007-02-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135440-A1 | Amide derivatives bearing a cyclopropylaminoacarbonyl substituent useful as cytokine inhibitors | IL2, IL6, IL1B | MAPK11 2179/4885MAPK14 1549/4885MAPK13 2573/4885 |
| US-20120004243-A1 | AMIDE DERIVATIVES BEARING A CYCLOPROPYLAMINOACARBONYL SUBSTITUENT USEFUL AS CYTOKINE INHIBITORS | IL2, IL6, IL1B | MAPK11 2262/4885MAPK14 1594/4885MAPK13 2611/4885 |
| US-20130035346-A1 | AMIDE DERIVATIVES BEARING A CYCLOPROPYLAMINOACARBONYL SUBSTITUENT USEFUL AS CYTOKINE INHIBITORS | IL2, IL6, IL1B | MAPK11 2262/4885MAPK14 1594/4885MAPK13 2611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.